On 16 September 2026, the Maharashtra Food and Drug Administration revealed extreme price markups on medical devices, with intravenous infusion sets showing a markup of 2,841 percent. The trade price for an IV set is 11.05 rupees while the maximum retail price printed on the package is 325 rupees.

The investigation covered 12,083 entities that have been issued notices. Disposable masks were found to have a 153 percent markup. The regulator said patients cannot bargain or choose devices and are left vulnerable to inflated prices set by manufacturers.

Medical devices currently lack price controls that apply to scheduled medicines, allowing unchecked profiteering. An association of medical device manufacturers supported the call for a fair pricing policy, noting the ethical and competitive need for reform.

The survey examined commonly used hospital items including intravenous sets, syringes, nebulisers, oxygen masks and other hospital consumables. An infusion set purchased for eleven rupees had a maximum retail price of two hundred and one rupees. A ten millilitre syringe bought for six rupees and seventy-five paise was marked at fifty-seven rupees and twenty paise, while a hypodermic needle bought for one rupee had a printed price of three rupees and thirty paise. Nebuliser products showed similar gaps, with one item bought for forty rupees carrying a maximum retail price of seven hundred and fifteen rupees, and an adult nebuliser mask kit bought for forty-five rupees marked at six hundred and fifty-two rupees.

Hospital industry groups have pushed back on applying fixed markups to medical consumables. Nathealth, the private hospitals' body, argues that hospitals are not simple resellers, with Secretary General Siddhartha Bhattacharya stating that sophisticated medical devices require clinical evaluation, specialized storage, trained staff, and safety compliance before reaching patients. The Association of Healthcare Providers of India noted that hospitals do not set maximum retail prices, which are determined by manufacturers and regulated by the National Productivity and Reliability Authority, adding that price increases for non-scheduled medical devices are capped at ten percent annually by central government regulation.

The federal government has initiated consultations with private hospitals regarding the pricing of surgical consumables and medical devices, following concerns raised by Maharashtra FDA Commissioner Tukaram Mundhe. The Department of Pharmaceuticals organized meetings with major private hospital operators including Max Healthcare, Jeewan Hospital, Marengo Asia, Aakash Healthcare, and Yashoda, along with representatives from the Delhi-NCR chapter of the Federation of Indian Chambers of Commerce and Industry. Hospital representatives argued that printed maximum retail prices do not directly translate into hospital profits, emphasizing that additional costs cover administration, infection control, nursing care, and storage.

Commissioner Mundhe has written to the Department of Pharmaceuticals and the National Pharmaceutical Pricing Authority, requesting a review of the survey findings and appropriate action, including capping trade margins or bringing essential device categories under structured price monitoring. The findings have been submitted to the department of pharmaceuticals as a policy recommendation for stronger price oversight and transparency in medical device pricing.

The pricing debate coincides with government efforts to expand domestic medical-device manufacturing and reduce import dependence. India's medical-device market is projected to reach around fifty billion dollars by 2030, while approximately eighty percent of domestic sales currently come from imported devices. The Production Linked Incentive scheme for medical devices has approved twenty-six companies with committed investment of around one thousand three hundred and thirty crore rupees, and four medical-device parks have received financial assistance across Uttar Pradesh, Tamil Nadu, Madhya Pradesh, and Himachal Pradesh.

The Drugs Prices Control Order, 2013 gives the government authority to regulate prices of drugs and certain medical devices, with the National Pharmaceutical Pricing Authority monitoring prices and availability. The National List of Essential Medicines forms the basis for bringing devices under price controls, and paragraph nineteen of the order allows temporary ceiling prices during extraordinary circumstances. The authority has received twenty-four overcharging complaints and ten shortage cases related to medical devices since 2018, with notices issued where necessary.

Past investigations have not stopped persistent overcharging in private hospitals, eroding trust and affordability in the healthcare system.

Original Sources/Tags: deccanherald.com, business-standard.com, timesofindia.indiatimes.com, ndtvprofit.com, health.economictimes.indiatimes.com, etvbharat.com, deccanherald.com, livemint.com, (maharashtra), (manufacturers)

The article provides no actionable information for a normal person. It does not offer clear steps, choices, instructions, or tools that a reader can use soon. While it mentions extreme price markups on medical devices, it gives no guidance on how someone might verify these claims, report concerns, or make informed healthcare purchasing decisions. The article references an investigation covering 12,083 entities but does not provide resources or contacts that readers could realistically access. There is nothing a reader can do or try based on this text alone.

The educational depth is shallow. The article states facts about markup percentages and price differences but does not explain how medical device pricing works, how regulatory oversight functions, or how healthcare cost structures operate. It mentions statistics like the 2,841 percent markup and 153 percent markup but does not explain why these numbers matter or how they were determined. The information remains superficial and unexplained, offering no deeper understanding of the systems behind the controversy.

Personal relevance is limited. The article affects only a small group of people who purchase medical devices or navigate private healthcare systems. Most normal people do not encounter situations where they directly buy intravenous infusion sets or disposable masks at retail prices. The controversy connects to broader issues of healthcare affordability and fair pricing, but the article does not explain how these issues affect everyday financial decisions or responsibilities. The relevance is restricted to rare situations involving medical care procurement.

The public service function is absent. The article simply recounts a story without offering context, warnings, or guidance that helps the public act responsibly. It does not provide safety information, emergency contacts, or advice on how to identify fair pricing in healthcare. The piece appears to exist mainly for attention rather than service, presenting opinions without verification or practical help for readers who want to make better healthcare choices.

No practical advice is given. The article does not provide steps or tips that an ordinary reader can realistically follow. It mentions regulatory findings but does not translate this into actionable guidance for consumers, such as how to research medical device costs or advocate for transparent pricing. The guidance is completely absent, making it impossible for readers to apply the information in their daily lives.

There is no long term impact. The article focuses entirely on a short lived event involving a specific regulatory investigation. It offers no lasting benefit for planning ahead, staying safer, improving healthcare habits, or avoiding similar problems in the future. The information does not help readers build stronger decision making skills or develop better consumer practices over time.

The emotional and psychological impact is negative. The article creates feelings of injustice and helplessness without providing any way for readers to respond constructively. It presents a problem but leaves readers with no tools to address their concerns or make different choices. The piece harms more than it helps by amplifying outrage without offering solutions.

There are signs of clickbait language. The article uses dramatic claims about "extreme price markups" and "unchecked profiteering" that add emotional weight but no substance. It overpromises by suggesting this controversy matters to most people while failing to deliver any meaningful information or guidance. The sensational framing relies on shock value rather than useful content.

The article misses clear opportunities to teach or guide. It presents a problem involving healthcare pricing but fails to provide steps, examples, or context that would help readers learn more. It does not explain how to research medical costs, identify fair pricing, or advocate for transparency in healthcare. The piece offers no way for readers to verify claims or make informed decisions.

A normal person can protect themselves by developing basic reasoning skills when encountering similar healthcare controversies. When reading about medical pricing disputes, compare multiple independent accounts to get a fuller picture. Examine patterns across different cases to understand whether issues are isolated or systemic. Consider general safety practices like researching treatment costs before procedures, asking healthcare providers for itemized bills, and understanding insurance coverage details. Use common sense approaches such as checking official healthcare pricing guidelines, looking for transparent billing practices, and seeking second opinions for expensive treatments. These methods help build better decision making habits without relying on unverified claims from any single source.

When facing healthcare decisions, start by gathering basic information about costs and alternatives. Ask providers to explain pricing clearly and request written estimates when possible. Understand your insurance benefits and coverage limits before receiving care. Keep records of all medical expenses and billing statements. If prices seem unusually high, ask for explanations and compare costs across different facilities. Remember that you have the right to ask questions about medical charges and seek more affordable options when available. Building these habits over time creates a foundation for better healthcare decision making and financial protection.

The text uses strong words like "extreme price markups" and "unchecked profiteering" to make readers feel angry at medical companies. These words push a feeling that big companies are stealing from sick people. The bias helps critics who want to shame manufacturers. It hides that some costs may be needed for research or safety. The words make the story sound like a fight between good and bad.

The text says "patients cannot bargain or choose devices" to make readers feel sad and helpless. This trick hides that hospitals or insurance may also set prices. The bias helps poor patients and hurts rich companies. It hides that some patients do have choices in private care. The words make the price problem seem only about power, not other causes.

The text says "allowing unchecked profiteering" to make all manufacturers look greedy. This trick hides that some companies may follow fair rules. The bias helps regulators who want more control. It hides that not every company overcharges on purpose. The words make the whole industry sound evil without proof.

The text says "eroding trust and affordability" to make readers feel scared about the healthcare system. This trick hides that prices may rise for many reasons. The bias helps people who want government control. It hides that some price growth comes from new technology. The words make the system sound broken and hopeless.

The text says "An association of medical device manufacturers supported the call" to make the industry look honest. This trick hides that the group may protect its own profits. The bias helps the regulator by showing some agreement. It hides that the group did not admit wrongdoing. The words make the reform seem fair and shared.

The text uses numbers like "2,841 percent" and "12,083 entities" to make the problem look huge. This trick hides that the sample may not show all cases. The bias helps the regulator by showing big proof. It hides that some prices may be fair. The numbers make the story feel certain and true.

The text says "Past investigations have not stopped persistent overcharging" to make readers feel the system always fails. This trick hides that some cases may have improved. The bias helps people who want new rules. It hides that enforcement may work in some places. The words make change seem impossible without more power.

The text says "maximum retail price printed on the package is 325 rupees" to make the markup look planned and fake. This trick hides that printed prices may include taxes or fees. The bias helps critics who say companies lie. It hides that some price gaps come from middlemen. The words make the company look sneaky on purpose.

The text says "patients are left vulnerable to inflated prices" to make readers feel sorry for sick people. This trick hides that insurance or governments may pay most bills. The bias helps poor patients and hurts rich companies. It hides that some patients have help. The words make the problem sound only about money, not care.

The text says "notices" were issued to many groups to make the action look strong and fair. This trick hides that notices may not lead to real change. The bias helps the regulator by showing effort. It hides that some groups may fight back. The words make the government look busy and right.

The text carries a strong feeling of anger that appears when it talks about extreme price markups on medical devices. The emotion is clear and intense because it uses shocking numbers like a 2,841 percent markup on IV sets and a 153 percent markup on disposable masks. This anger is meant to show that something deeply unfair is happening to patients who need these medical supplies. The purpose is to make the reader feel upset and ready to demand change.

A deep sense of sadness and disappointment is present when the text describes how patients cannot bargain or choose their devices. The emotion is moderate but steady because it highlights the vulnerability of people who are already sick or injured. This sadness helps the reader understand that the healthcare system is failing those who need it most. The purpose is to create sympathy for patients who are being taken advantage of.

There is also a feeling of concern and worry that runs through the text when it mentions unchecked profiteering and the lack of price controls on medical devices. The emotion is steady because it warns the reader that this problem could keep getting worse. This worry is meant to show that the situation is serious and needs immediate attention. The purpose is to make the reader feel alarmed about the future of healthcare affordability.

A tone of determination and urgency appears when the text says the regulator has issued notices to 12,083 entities. The emotion is strong because it shows that action is being taken against the overcharging. This determination is meant to show that the system is responding to the problem. The purpose is to build trust that the authorities are working to fix the issue.

There is also a feeling of hope and support when the text mentions that an association of medical device manufacturers agreed with the call for a fair pricing policy. The emotion is moderate but positive because it suggests that even the industry recognizes the need for change. This hope is meant to show that reform is possible when all sides work together. The purpose is to inspire confidence that the healthcare system can become fairer.

These emotions guide the reader’s reaction by creating a story of injustice followed by action and hope. The anger and concern make the reader pay close attention to the seriousness of the problem. The sadness and worry help the reader feel sympathy for patients who are being hurt. The determination and hope encourage the reader to believe that change is possible. Together, these feelings shape the message to show that extreme price markups are wrong and must be stopped.

The writer uses several tools to make the emotions stronger. Action words like revealed, issued notices, and supported create a sense of movement and urgency. Repeating the idea of extreme markups and unchecked profiteering makes the reader feel the weight of the problem. Specific numbers like 2,841 percent and 12,083 entities make the story feel real and technical, which increases the sense of seriousness. The phrase patients cannot bargain or choose devices uses simple but powerful language to show that people are powerless. The contrast between the low trade price of 11.05 rupees and the high retail price of 325 rupees makes the unfairness feel extreme and shocking. The mention of past investigations that did not stop overcharging creates a sense of frustration and urgency. All these tools help the writer steer the reader’s attention toward the need for action, accountability, and reform in the healthcare system.